Immunotherapeutics

Projects

ADAC

Antibody Drug Affinity Conjugate (ADAC) is a technology platform that we have developed together with the SciLifeLab DDD drug development platform. We use this platform to improve targeted drug delivery. Through commercialization, the technology is also applied in the pharmaceutical industry via the company Strike Pharma AB.

Bladder Cancer

Over the years, we have studied bladder cancer by developing new model systems, drugs, and drug combinations for its treatment. Many patients who develop bladder cancer have a localized form that does not spread. However, some develop cancer that invades the muscle, and these patients have a poorer prognosis. We are currently investigating how a specific immune cell influences the surrounding tissue at the tumor site, making it easier for the tumor to spread, as well as the factors that contribute to this risk of dissemination.

ID-Flow

We have developed a whole-blood model as an ex vivo human system to study infusion reactions when drugs encounter blood. This model has been used to assess the safety and efficacy of immunotherapeutic drugs in healthy volunteers and to evaluate safety and efficacy in patients. The model can help minimize the need for animal use in drug studies (3R principle). Through commercialization, the technology is also offered for industrial use in the pharmaceutical industry via the company Immuneed AB.

Myeloid Cell Targeting

We study how myeloid cells can be modulated using various antibodies that target and influence these cells. We investigate their activity, maturation, and interactions with T cells in the body. Through these studies, we aim to understand how pharmaceutical control of the immune system can be improved in different disease conditions.

Novel antibiotics

We study how we can adapt novel drug formats to enable targeting of difficult to treat infections together with SciLifeLab under the EU funded postdoctoral program PULSE in collaboration with the SciLifeLab DDD platform.

Funding support

We are thankful for the generous support we have from SciLifeLab DDD platform, EU Horizon PhD and postdoctoral network funding, Swedish Research Council project grant support, Swedish Cancer Foundation Research grant support and Vinnova along with our industrial collaborations. We are also grateful to all our national and international collaborators.